Full text is available at the source.
Abstract
A single infusion of a CRISPR-based treatment resulted in over 90% reduction of circulating ANGPTL3 protein in nonhuman primates.
- Targeted inactivation of ANGPTL3 is linked to reductions of approximately 40 to 50% in low-density lipoprotein cholesterol (LDL-C).
- The treatment caused a reduction of 50 to 70% in triglyceride levels in hyperlipidemic models.
- The gene-editing approach demonstrated no detectable off-target effects at around 3000 candidate sites.
- Durability of the ANGPTL3 inactivation was confirmed for up to 3 years after a single dose in nonhuman primates.
- The findings support the initiation of a first-in-human clinical trial for patients with refractory hyperlipidemia syndromes.
Simplified